This site is intended for healthcare professionals only
DiabetesontheNet Logo


Diabetes Digest

Issue:

Early View

Share this article

Faster-acting insulin aspart non-superior to aspart in pump therapy

Devices – April 2019 digest

Onset 5 study evaluating the efficacy and safety of fast-acting insulin aspart administered by pump to people with type 1 diabetes.

Klonoff DC, Evans ML, Lane W et al (2019) A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5). Diabetes Obes Metab 21: 961–7
 

  • Insulin pump therapy can improve glycaemic control and reduce the risk of hypoglycaemia in people with type 1 diabetes; however, as only about a third of these individuals achieve a target HbA1c of <53 mmol/mol (<7%), there is a need to develop insulins with actions that more closely resemble physiological insulin in addition to using modern insulin delivery and monitoring systems.
  • Onset 5 aimed to evaluate the safety and efficacy of fast-acting insulin aspart (Fiasp) compared to insulin aspart when administered via pump therapy in people with type 1 diabetes.
  • A total of 472 participants were randomised to Fiasp or insulin aspart for 16 weeks to compare their effects on baseline HbA1c (the primary endpoint). A bolus was administered at the start of each meal and change in post-prandial glucose was measured.
  • Sixteen weeks after randomisation, researchers found that baseline HbA1c had dropped from 61.7 mmol/mol (7.8%) in both arms at the start of the trial to 57.8 mmol/mol (7.44%) in the Fiasp group and 56.8 mmol/mol (7.35%) in the insulin aspart group. Fiasp resulted in a greater 1-hour post-prandial glucose change as well as a greater risk of severe hypoglycaemia within an hour of receiving the mealtime bolus. 
  • Researchers declared Fiasp to be non-inferior to insulin aspart. No significant difference was found in the proportion of participants achieving target HbA1c. They concluded that the drop in post-prandial glucose levels reflected the faster onset of action and early glucose-lowering effect of Fiasp.
  • Fiasp led to a superior post-prandial glucose reduction compared to insulin aspart and was found to be safe and effective for administration via pump in people with type 1 diabetes. 

Click here to access the article in full

Related content
;
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.